Chemotherapy and Cetuximab in Patients Undergoing Surgery for Peritoneal Carcinomatosis From Colorectal Cancer

Stopped In 2008, new data highlighted that Cetuximab had no efficacy in case of KRAS mutation. As such, eligibility criteria were revised and limited to KRAS wild-type. Inclusions were thus slown down considerably, and the trial was stopped.

Conditions

• Colorectal Cancer
• Primary Peritoneal Cavity Cancer

Interventions

• BIOLOGICAL: cetuximab
• DRUG: fluorouracil
• DRUG: leucovorin calcium
• DRUG: oxaliplatin
• PROCEDURE: adjuvant therapy
• PROCEDURE: therapeutic conventional surgery

Sponsor

Institut Bergonié

Collaborators

• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]
• [object Object]